IDEAYA Bioscience’s rare cancer drug shows benefit in interim Phase II data, with the company announcing the drugs Phase III ...

The new safety data from Phase III and I trials showing an absence of postinjection syndrome, a rare and serious side effect ...

Actinium reported data from the Phase III SIERRA trial of Iomab-B for relapsed or refractory acute myeloid leukaemia (r/r AML ...

The trial compares Eli Lilly’s lutetium zadavotide guraxetan with Astellas’s Xtandi or Janssen’s Zytiga for mPRPC.

Summit Therapeutics and Akeso published results for the Phase III HARMONi-2 trial, which tested ivonescimab, a bispecific ...

The blinded blood pressure monitor and scale allows blind data monitoring, where participants can take readings but not see ...

Moderna's mRNA-4359 has shown early signs of efficacy, activating key proteins to trigger an immune response for cancer ...

The Clinical Trials Arena team investigates assets in infectious diseases, metabolic disorders, oncology and ophthalmology.

Pfizer’s cancer cachexia candidate has provided patients with clinically meaningful weight gain in a Phase II trial, with the ...

Antimicrobial drugs are widely used around the world to treat infections. However, the overuse of antimicrobials has resulted ...

At the Clinical Trial Supply West Coast 2024 conference, serial biotech entrepreneur Umar Hayat said science should be ...

Oncternal is halting the development of two cancer candidates, ONCT-534 and ONCT-808, after disappointing trial results.